Jacobs Levy Equity Management, Inc Enanta Pharmaceuticals Inc Transaction History

Jacobs Levy Equity Management, Inc

  • $25.8 Billion
  • Q4 2024

A detailed history of Jacobs Levy Equity Management, Inc transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 290,011 shares of ENTA stock, worth $2.13 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
290,011
Previous 191,726 51.26%
Holding current value
$2.13 Million
Previous $1.99 Million 16.15%
% of portfolio
0.01%
Previous 0.01%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025
BUY
$5.75 - $12.99 $565,138 - $1.28 Million
98,285 Added 51.26%
290,011 $1.67 Million
Q3 2024

Nov 14, 2024
SELL
$10.05 - $16.54 $28,552 - $46,990
-2,841 Reduced 1.46%
191,726 $1.99 Million
Q2 2024

Aug 14, 2024
SELL
$11.43 - $17.02 $1,863 - $2,774
-163 Reduced 0.08%
194,567 $2.52 Million
Q1 2024

May 15, 2024
SELL
$10.08 - $17.46 $3.69 Million - $6.4 Million
-366,291 Reduced 65.29%
194,730 $3.4 Million
Q4 2023

Feb 14, 2024
BUY
$8.18 - $10.78 $1.76 Million - $2.32 Million
215,370 Added 62.31%
561,021 $5.28 Million
Q3 2023

Nov 16, 2023
SELL
$11.09 - $22.13 $18,819 - $37,554
-1,697 Reduced 0.49%
345,651 $3.86 Million
Q2 2023

Aug 14, 2023
BUY
$20.68 - $39.85 $18,467 - $35,586
893 Added 0.26%
347,348 $7.43 Million
Q1 2023

May 15, 2023
SELL
$38.82 - $54.59 $101,048 - $142,097
-2,603 Reduced 0.75%
346,455 $14 Million
Q4 2022

Feb 14, 2023
SELL
$40.77 - $53.73 $132,298 - $174,353
-3,245 Reduced 0.92%
349,058 $16.2 Million
Q3 2022

Nov 15, 2022
BUY
$48.29 - $71.27 $2.64 Million - $3.9 Million
54,771 Added 18.41%
352,303 $18.3 Million
Q2 2022

Aug 15, 2022
BUY
$38.13 - $76.93 $728,626 - $1.47 Million
19,109 Added 6.86%
297,532 $14.1 Million
Q1 2022

May 16, 2022
BUY
$56.06 - $74.11 $464,905 - $614,594
8,293 Added 3.07%
278,423 $19.8 Million
Q4 2021

Feb 14, 2022
BUY
$60.19 - $97.37 $982,060 - $1.59 Million
16,316 Added 6.43%
270,130 $20.2 Million
Q3 2021

Nov 15, 2021
SELL
$41.02 - $58.65 $235,413 - $336,592
-5,739 Reduced 2.21%
253,814 $14.4 Million
Q2 2021

Aug 16, 2021
BUY
$43.76 - $53.11 $756,872 - $918,590
17,296 Added 7.14%
259,553 $11.4 Million
Q1 2021

May 17, 2021
SELL
$41.69 - $54.95 $252,766 - $333,161
-6,063 Reduced 2.44%
242,257 $11.9 Million
Q4 2020

Feb 16, 2021
SELL
$41.16 - $47.47 $318,743 - $367,607
-7,744 Reduced 3.02%
248,320 $10.5 Million
Q3 2020

Nov 16, 2020
SELL
$43.36 - $53.53 $355,421 - $438,785
-8,197 Reduced 3.1%
256,064 $11.7 Million
Q2 2020

Aug 17, 2020
BUY
$46.37 - $57.58 $4.33 Million - $5.38 Million
93,476 Added 54.73%
264,261 $13.3 Million
Q1 2020

May 15, 2020
BUY
$40.22 - $62.0 $3.42 Million - $5.27 Million
84,998 Added 99.08%
170,785 $8.78 Million
Q4 2019

Feb 14, 2020
BUY
$57.95 - $66.61 $835,233 - $960,049
14,413 Added 20.19%
85,787 $5.3 Million
Q3 2019

Nov 14, 2019
BUY
$60.08 - $88.17 $803,269 - $1.18 Million
13,370 Added 23.05%
71,374 $4.29 Million
Q2 2019

Aug 13, 2019
BUY
$81.3 - $97.35 $4.72 Million - $5.65 Million
58,004 New
58,004 $4.89 Million
Q4 2018

Feb 14, 2019
SELL
$65.41 - $84.65 $1.75 Million - $2.27 Million
-26,822 Closed
0 $0
Q3 2018

Nov 14, 2018
BUY
$85.46 - $126.37 $1.21 Million - $1.79 Million
14,145 Added 111.58%
26,822 $2.29 Million
Q2 2018

Aug 14, 2018
SELL
$81.85 - $120.51 $1.31 Million - $1.93 Million
-16,043 Reduced 55.86%
12,677 $1.47 Million
Q1 2018

May 15, 2018
SELL
$57.91 - $92.15 $39,378 - $62,662
-680 Reduced 2.31%
28,720 $2.32 Million
Q4 2017

Feb 13, 2018
BUY
$45.65 - $59.37 $1.34 Million - $1.75 Million
29,400
29,400 $1.73 Million

Others Institutions Holding ENTA

# of Institutions
108
Shares Held
19.7M
Call Options Held
9.7K
Put Options Held
12.4K
View Full List

About ENANTA PHARMACEUTICALS INC

ENTA Quotes by TradingView
  • Ticker ENTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,724,900
  • Market Cap $152M
  • Description
  • Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...
More about ENTA
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email